Balance Sheet
Cash Flow Statement
Change in Accured ExpensesChange in Accured Expenses
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Change in Accured Expenses (2020 - 2025)

China SXT Pharmaceuticals has reported Change in Accured Expenses over the past 6 years, most recently at $3.3 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 11.77% year-over-year to $3.3 million; the TTM value through Sep 2025 reached $3.3 million, up 11.77%, while the annual FY2025 figure was $2.9 million, 6.11% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $3.3 million at China SXT Pharmaceuticals, up from $2.9 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $3.5 million in Q1 2022 and troughed at $2.8 million in Q1 2024.
  • A 5-year average of $3.2 million and a median of $3.2 million in 2023 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: surged 36.71% in 2021 and later dropped 11.89% in 2024.
  • Year by year, Change in Accured Expenses stood at $3.4 million in 2021, then fell by 2.46% to $3.3 million in 2022, then fell by 0.89% to $3.2 million in 2023, then dropped by 10.05% to $2.9 million in 2024, then rose by 11.77% to $3.3 million in 2025.
  • Business Quant data shows Change in Accured Expenses for SXTC at $3.3 million in Q3 2025, $2.9 million in Q1 2025, and $2.9 million in Q3 2024.